Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

Journal of Thoracic Oncology

Volumn 12, Issue 3, 2017, Pages 567-572

  Ho, Chao Chi ^a   Liao, Wei Yu ^a   Lin, Chih An ^b   Shih, Jin Yuan ^a   Yu, Chong Jen ^a   Chih Hsin Yang, James ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Acquired resistance; BRAF V600E; NSCLC; T790M; Targeted therapy

Indexed keywords

ARGININE; B RAF KINASE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GLUTAMIC ACID; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; OSIMERTINIB; PEMETREXED; PROTEIN KINASE B; VALINE; BRAF PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER STAGING; CASE REPORT; CELL CULTURE; CELL GROWTH; COLONY FORMATION; DRUG SENSITIVITY; EXON; GENOTYPE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MALE; MALIGNANT PLEURA EFFUSION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUTATIONAL ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; ADENOCARCINOMA; BONE TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SECONDARY;

ADENOCARCINOMA; ADULT; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PHOSPHORYLATION; PIPERAZINES; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 85015313813     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.11.2231     Document Type: Article

References (15)

1. 1 Tan, D.S., Yom, S.S., Tsao, M.S., et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 11 (2016), 946–963.
2. 2 Jänne, P.A., Yang, J.C., Kim, D.W., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
3. 3 Thress, K.S., Paweletz, C.P., Felip, E., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21 (2015), 560–562.
4. 4 Kim, T.M., Song, A., Kim, D.W., et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol 10 (2015), 1736–1744.
5. 5 Planchard, D., Loriot, Y., Andre, F., et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 26 (2015), 2073–2078.
6. 6 Liu, X., Ory, V., Chapman, S., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 180 (2012), 599–607.
7. 7 Su, K.Y., Chen, H.Y., Li, K.C., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30 (2012), 433–440.
8. 8 Hsu, K.H., Ho, C.C., Hsia, T.C., et al. Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. PloS One, 10, 2015, e0120852.
9. 9 Sholl, L.M., Aisner, D.L., Varella-Garcia, M., et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thorac Oncol 10 (2015), 768–777.
10. 10 Paik, P.K., Arcila, M.E., Fara, M., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29 (2011), 2046–2051.
11. 11 Planchard, D., Kim, T.M., Mazieres, J., et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17 (2016), 642–650.
12. 12 Ohashi, K., Sequist, L.V., Arcila, M.E., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109 (2012), E2127–E2133.
13. 13 Hata, A., Yoshioka, H., Fujita, S., et al. Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac Oncol 5 (2010), 1524–1528.
14. 14 Takamochi, K., Oh, S., Matsuoka, J., Suzuki, K., Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer 75 (2012), 313–320.
15. 15 Crystal, A.S., Shaw, A.T., Sequist, L.V., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346 (2014), 1480–1486.